|本期目录/Table of Contents|

[1]翟 翠,宋 旸,苏小凡,等.哮喘患者吸入性糖皮质激素治疗依从性的决定因素分析[J].中华肺部疾病杂志,2020,(03):302-306.[doi:10.3877/cma.j.issn.1674-6902.2020.03.003]
　Chang Jie,Gao Hongxiang,Yang Shuanying,et al.Efficacy and survival analysis of apatinib in treatment of beyond second-line small cell lung cancer[J].,2020,(03):302-306.[doi:10.3877/cma.j.issn.1674-6902.2020.03.003]
点击复制

哮喘患者吸入性糖皮质激素治疗依从性的决定因素分析(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2020年03期
页码:
302-306
栏目:
论著
出版日期:
2020-06-20

文章信息/Info

Title:
Efficacy and survival analysis of apatinib in treatment of beyond second-line small cell lung cancer
作者:
翟 翠; 宋 旸; 苏小凡; 王青婷; 史文花; 李满祥
710061 西安,西安交通大学第一附属医院呼吸与危重症医学科
Author(s):
Chang Jie1;  Gao Hongxiang1;  Yang Shuanying2;  Du Jianfei1.
1Department of Oncology, Chang'an Hospital, Xi'an 710016, China; 2Department of Respiratory and Critical Care Medicine, College of Medicine, Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an 710004, China
关键词:
支气管哮喘;  糖皮质激素;  治疗依从性
Keywords:
Apatinib;  Small cell lung cancer;  Vascular endothelial growth factor
分类号:
R562
DOI:
10.3877/cma.j.issn.1674-6902.2020.03.003
摘要:
目的 探讨阿帕替尼应用于二线以上进展期小细胞肺癌的临床疗效、不良反应、影响因素和生存分析。方法 收集二线以上化疗失败的小细胞肺癌患者30例,均给予甲磺酸阿帕替尼片500 mg/次/d口服,28 d为一疗程,有Ⅲ-Ⅳ级不良反应时减量至250 mg/次/d,至疾病进展或药物不良反应无法耐受则停药,观察服药2个疗程的临床疗效,及整个服药期间的不良反应。通过Kaplan-Meier法分析生存情况和影响因素,将有统计学意义的影响因素纳入多因素Cox比例风险模型进行分析。结果 30例患者经过2个疗程评估客观缓解率(ORR)为36.6%,疾病控制率(DCR)为66.6%,中位无疾病进展期(PFS)4.0个月(95%CI 2.864～5.136个月),中位总生存期(OS)6.0个月(95%CI 4.555～7.445个月)。治疗期间主要不良反应为高血压发生率56.6%,蛋白尿发生率33.33%,血小板减少率56.6%,白细胞减少率86.6%,丙氨酸氨基转移酶升高16.6%,胃肠道反应10.0%,疲劳33.3%,手足综合证23.3%,无Ⅳ级以上不良反应。应用Kaplan-Meier法和多因素Cox回归模型分析低钠血症(HR=3.693,95%CI 为1.043～13.082,P=0.043)、高血压(HR=0.279,95%CI 为0.090～0.869,P=0.028)是PFS的独立影响因素,低钠血症(HR=8.675,95%CI 为2.284～32.947,P=0.002)、分期(HR=4.915,95%CI 为1.151～20.978,P=0.032)、高血压(HR=0.128,95%CI 为0.031～0.537,P=0.005)是OS的独立影响因素。结论 阿帕替尼应用于二线以上进展期小细胞肺癌存在疗效,不良反应可耐受。治疗前期出现低钠血症及分期较高的患者预后不佳,不良反应出现高血压应用阿帕替尼可能存在生存优势。
Abstract:
Objective To explore the clinical efficacy, toxicity, influence factors and survival analysis of apatinib in the patients with advanced small cell lung cancer(SCLC)after failure of beyond second-line treatment. Methods Thirty SCLC patients after failure of beyond second-line chemotherapy received oral administration of 500 mg of apatinib once a day, 28 days as a cycle, which was reduced to 250 mg once a day due to obvious adverse reactions or drug withdrawal due to disease progression or intolerance. The clinical efficacy of two courses of medication and the adverse reactions during the whole period of medication were observed. The survival and influencing factors were analyzed by Kaplan-Meier method, and the influencing factors with statistical significant difference were included in the multi-factor Cox proportional risk model. Results The objective response rate was 36.66% and the disease control rate was 66.6% after two cycles of medication. The median progression free survival(PFS)was 4.0 months(95%CI 2.864～5.136), the median overall survival(OS)was 6.0 months(95%CI 4.555～7.445), and the main adverse reactions were hypertension(56.6%), proteinuria(33.3%), thrombocytopenia(56.6%), leukopenia(86.6%), abnormal liver function(16.6%), diarrhea(10.0%), fatigue(33.3%), and hand-foot syndrome(23.3%). Grade Ⅳ adverse reactions were not found. Hyponatremia(HR=3.693, 95%CI 1.043～13.082, P=0.043)and hypertension(HR=0.279, 95%CI 0.090～0.869, P=0.028)were independent influencing factors of PFS with Kaplan-Meier method and multivariate Cox regression model. Hyponatremia(HR=8.675, 95%CI 2.284～32.947, P=0.002), staging(HR=4.915, 95%CI 1.151～20.978, P=0.032)and hypertension(HR=0.128, 95%CI 0.031～0.537, P=0.005)were independent influencing factors of OS. Conclusion Apatinib is effective in the treatment of advanced SCLC above the second line. The prognosis of the patients with hyponatremia and higher stages before treatment is not good, and the patients with side effects of hypertension may have survival advantages by using apatinib.

参考文献/References:

1 王长征. 改善支气管哮喘控制现状,需要重视患者的长期管理[J/CD]. 中华肺部疾病杂志(电子版), 2013, 6(4): 296-298.
2 李 喆, 莫琳芳, 任成山. 噻托溴铵在治疗支气管哮喘中的临床应用[J/CD]. 中华肺部疾病杂志(电子版), 2017, 10(3): 358-360.
3 Manuyakorn W, Howarth PH, Holgate ST. Airway remodelling in asthma and novel therapy[J]. Asian Pac J Allergy Immunol, 2013, 31: 3-10.
4 Masoli M, Fabian D, Holt S, et al. The global burden of asthma: executive summary of the GINA Dissemination Committee report[J]. Allergy, 2004, 59: 469-478.
5 Nong Y, Lin JT, Chen P, et al. [The relationship between smoking status and epidermiology of asthma in people aged over 14 years in China][J]. Zhonghua Nei Ke Za Zhi,2017, 56: 485-489.
6 Durrani SR, Viswanathan RK, Busse WW. What effect does asthma treatment have on airway remodeling Current perspectives[J]. J Allergy Clin Immunol, 2011, 128: 439-448.
7 Wallace DV, Dykewicz MS, Oppenheimer J, et al. Pharmacologic Treatment of Seasonal Allergic Rhinitis: Synopsis of Guidance From the 2017 Joint Task Force on Practice Parameters[J]. Ann Intern Med, 2017, 167: 876-881.
8 Mellins RB, Evans D, Clark N, et al. Developing and communicating a long-term treatment plan for asthma[J]. Am Fam Physician,2000, 61: 2419-2428, 2433-2434.
9 Elamin SA, Merghani TH, Alawad AO. Adequacy of asthma management among patients attending referred clinics in Khartoum[J]. Khartoum Med J, 2011, 4: 532-538.
10 Jentzsch NS, Camargos P, Sarinho ES, et al. Adherence rate to beclomethasone dipropionate and the level of asthma control[J]. Respir Med,2012, 106: 338-343.
11 Bender B, Zhang L. Negative affect, medication adherence, and asthma control in children[J]. J Allergy Clin Immunol, 2008, 122: 490-495.
12 Duncan CL, Hogan MB, Tien KJ, et al. Efficacy of a parent-youth teamwork intervention to promote adherence in pediatric asthma[J]. J Pediatric Psychol, 2012, 38: 617-628.
13 McGrady ME, Hommel KA. Medication adherence and health care utilization in pediatric chronic illness: a systematic review[J]. Pediatrics, 2013, 132: 730-740.
14 Nasser S. An imperfect “PAST” lessons learned from the national review of asthma deaths(NRAD)UK[J]. Respir Res, 2016, 17: 87.
15 Chapman S, Dale P, Svedsater H, et al. Adherence to asthma medication and preferences for once-daily treatment: Importance of treatment intrusiveness and patient beliefs[J]. Eur Respir J, 2016, 48: PA5018.
16 Nathan RA, Sorkness CA, Kosinski M, et al. Pendergraft. Development of the asthma control test: a survey for assessing asthma control[J]. J Allergy Clin Immunol, 2004, 113: 59-65.
17 Kwon HS, Lee SH, Yang MS, et al. Correlation between the Korean version of Asthma Control Test and health-related quality of life in adult asthmatics[J]. J Korean Med Sci, 2008, 23: 621-627.
18 James DR, Lyttle MD. British guideline on the management of asthma: SIGN Clinical Guideline 141, 2014[J]. Arch Dis Child Educ Pract Ed, 2016, 101: 319-322.
19 Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary[J]. Eur Respir J, 2008, 31: 143-178.
20 “Global strategy for asthma management and prevention: GINA executive summary.” E.D. Bateman, S.S. Hurd, P.J. Barnes, J. Bousquet, J.M. Drazen, J.M. FitzGerald, P. Gibson, K. Ohta, P. O'Byrne, S.E. Pedersen, E. Pizzichini, S.D. Sullivan, S.E. Wenzel and H.J. Zar. Eur Respir J 2008; 31: 143-178[J]. Eur Respir J, 2018, 51:doi: 10.1183/13993003.51387-2007.
21 Szefler S, Weiss S, Tonascia J, et al. Long-term effects of budesonide or nedocromil in children with asthma[J]. N Engl J Med, 2000, 343: 1054-1063.
22 Perera BJ. Successful withdrawal of inhaled corticosteroids in childhood asthma[J]. Respirology, 2005, 10: 385-388.
23 Park CS. Size of Inhaled Corticosteroid and Small Airway Inflammation in Asthma[J]. Allergy Asthma Immunol Res, 2017, 9: 99-100.
24 Selroos O. A smarter way to manage asthma with a combination of a long-acting beta(2)-agonist and inhaled corticosteroid[J]. Ther Clin Risk Manag, 2007, 3: 349-359.
25 Aris R, Donohue JF, Ontjes D. Inhaled Corticosteroids and Fracture Risk[J]. Chest, 2005, 127: 5-7.
26 Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control[J]. Respir Med, 2011, 105: 930-938.
27 Roy A, Battle K, Lurslurchachai L, et al. Inhaler device, administration technique, and adherence to inhaled corticosteroids in patients with asthma[J]. Prim Care Respir J, 2011, 20: 148-154.
28 Expert Panel Report 3(EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007[J]. J Allergy Clin Immunol, 2007,120: S94-S138.
29 梁宗安, 刘春涛, 滕 鸿, 等. 健康教育对支气管哮喘患者生活质量的影响[J]. 中国呼吸与危重监护杂志, 2003, 2(1): 18-20.
30 Piquet J, Mellat M. [Fact sheet on asthma][J]. Soins, 1991,(555): 14-18.
31 Sullivan SD, Rasouliyan L, Russo PA, et al. Extent, patterns, and burden of uncontrolled disease in severe or difficult-to-treat asthma[J]. Allergy, 2007, 62: 126-133.
32 Janson SL, Earnest G, Wong KP, et al. Predictors of asthma medication nonadherence[J]. Heart Lung, 2008, 37: 211-218.

备注/Memo

备注/Memo:
基金项目: 国家自然科学基金资助项目(81330002; 81670051)
更新日期/Last Update: 2020-06-20